Gepirone ER not linked to sexual dysfunction in patients with depression

placebo group over the first 12 weeks, with headache and fatigue more common in women receiving elinzanetant."Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate to severe [vasomotor symptoms], " authors of the studies wrote.[